# Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)

> **NCT03274141** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 281 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT03274141
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-31
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-10-31
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274141, "Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03274141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*